抗癫痫新药氨己烯酸片的效果如何？

Ovation Pharmaceuticals of the United States recently stated that the FDA advisory committee unanimously voted to recommend the company's peripheral and central nervous system drug Sabril () as a single drug for the treatment of infantile spasms (IS). If the drug is ultimately approved, it would be the first and only drug approved to treat infantile spasms in the United States. Previously, the FDA advisory committee had unanimously approved vigabatrin tablets as an adjunctive drug for the treatment of adult patients with complex partial seizures (CPS) who have had an inadequate response to commonly used antiepileptic drugs. So, how effective is the new anti-epileptic drug vigabatrin tablets?

In a prospective observational study, 180 children with IS were treated with a vigabatrin regimen (50 mg/kg on day 1, 100 mg/kg on days 2 to 3, and 150 mg/kg in the following 2 weeks). The complete remission rate of spastic attacks was 56%, and the average response was effective on the fifth day of treatment. Large doses of vigabatrin are therefore more effective and have a rapid onset of action. A prospective randomized study on the efficacy of vigabatrin and ACTH on IS showed that the terminating rates of spasticity attacks of vigabatrin (150mg/kg·d) and ACTH (10IU/d) were 47.8% and 74.6%; it also showed that the efficacy of vigabatrin in treating cerebral malformations or TSC was better than ACTH, while ACTH was more effective in treating perinatal hypoxic-ischemic injury.

The side effects of vigabatrin tablets found in experiments include fatigue, hair loss, nystagmus, memory loss, confusion, edema, diplopia, weight gain, drowsiness, depression, gastrointestinal disorders, nervousness, paresthesia, headache, ataxia, dizziness, irritability and tremor, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.